Cerenion
Medical device company providing AI-based software for monitoring of brain function in intensive care.
- B2B
- saas
- manufacturing
- commission
- selling own inventory
- health
- health platform
- medical devices
- artificial intelligence
- hardware
- deep tech
- machine learning
- connected device
- horizon europe
- dt and ls
- spinout
- core ai
- analytics
- ai applications
- eit ecosystem
- slush24
- neurology
- eit health
- health it
- nordic rising star 2022
- physician support tools
- hospital
- medical diagnostics
- clinical decision support
- ai for medical imaging
- investor network (eit health)
- critical medical care
- investor network 2018 (eit health)
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor | €0.0 | round |
| investor | €0.0 | round | |
| investor investor | €0.0 | round | |
| investor | €0.0 | round | |
| investor investor investor | €0.0 | round | |
* | €3.3m | Series A | |
| Total Funding | 000k | ||
| EUR | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 |
| % growth | - | - | 83 % | (29 %) | (90 %) |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
Source: Company filings or news article
Related Content
Cerenion Oy is a science-based university spin-off specializing in advanced brain monitoring technology. The company operates in the medical device market, focusing on intensive care units (ICUs) where brain monitoring is often overlooked due to its complexity. Cerenion's core product is an AI-powered EEG (electroencephalogram) device that simplifies the process of monitoring brain function. This technology translates complex EEG data into easy-to-understand parameters, aiding medical professionals in making informed clinical decisions without altering patient care routines.
Cerenion's primary clients are hospitals and medical institutions that require reliable and efficient brain monitoring solutions. The company generates revenue through the sale of its certified Class IIb medical devices, which have received ISO 13485:2016 certification and are approved under the EU Medical Device Directive. Additionally, Cerenion has secured key patents in major markets like China, further solidifying its competitive edge.
The business model is centered around the development, certification, and distribution of its proprietary brain monitoring technology. By leveraging artificial intelligence, Cerenion aims to fill a critical gap in ICU patient care, providing a much-needed tool for neurophysiological assessment.
Keywords: AI-powered, EEG, brain monitoring, intensive care, medical device, ISO 13485, CE marked, neurophysiological, clinical decision-making, university spin-off.